Accelerating approval of imported drugs

Source: Sina Pharmaceutical News 2017-09-27 last week, CDE centralized the approval of imported drugs Gilead's new oral hepatitis C drug, sophibuvir tablets, ibuprofen's obipalin tablets, dasebuvir tablets, bringlingham's englejin tablets, Novo Nordisk's degu insulin injection were also approved for listing by the State Food and drug administration Suddenly I felt that the approval of new drugs by the State Administration was speeding up Then all the imported drugs have been approved In terms of the application and production of domestic new drugs in full swing, it is predicted that there will be a wave of listing upsurge in the future Now let's sort out the new drugs approved in the future Six of the eight new drugs applied for listing have been selected into the priority review list, including three TiNi anti-tumor drugs, one vaccine product, and one injection of nanofloxacin malate The new drug has been listed in the capsule formulation last year Pyrrolidine (known as oral Herceptin) of Hengrui medicine is to be listed in the 23rd batch of priority review list Geli's hepatitis C drug seems to be far away Approval is not far away, it seems that the price war of hepatitis C drugs is imminent Although new drugs in China have entered the harvest period, although they are me too drugs, the clinical efficacy of enrotinib, furaquinidine and pyrrolidine should not be inferior to that of imported drugs These new drugs should also have more dazzling data in clinical value compared with apatinib, sidazaniline, conbercept and exetinib which have been approved for marketing In addition to the five listed companies, these eight new drugs may increase their performance and market value returns Cutting edge biology, kangxinuo biology and Geli pharmaceutical all completed a relatively large amount of financing last year I believe that they are not far from IPO What is the return of investors? We'll see.